- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00387283
Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020
Pharmacokinetic Study of AVI-4020 in Cerebral Spinal Fluid Among Healthy Adult Males Following Intravenous Administration
During a clinical study of people with severe West Nile virus infections, it was determined that the drug AVI-4020 crossed the blood-brain barrier. This study will assess the amount of drug that goes across the blood-brain barrier and the drug levels measured in both the blood and urine.
The objective of this study is to find out how much and how fast this drug crosses this barrier.
Study Overview
Detailed Description
AVI-4020 was designed to interfere with West Nile virus translation, and has been shown to cross the blood-brain barrier in both normal and inflamed meninges in a clinical study in patients with severe West Nile virus disease.
At issue, is whether this observation is limited to AVI-4020 PMO drug, or is observed with other PMO drugs. This study is one of three to assess the specific ability of PMO drugs to cross the blood-brain barrier, using similar dosing, and PK assessment time points. In order to rigorously assess the pharmacokinetics, this study is being performed in healthy volunteers at a single point in time.
The ability of other PMO drugs to cross the blood-brain barrier will set the stage for future studies that exploit this product characteristic.
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Washington
-
Tacoma, Washington, United States, 98418
- NW Kinetics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult males 18 years to 64 years of age;
- Good general health (as evidenced by no chronic conditions, normal physical exam, vital signs within normal limits; laboratory evaluations within normal range)
- Signed and dated written informed consent form; and
- Willing to participate in all study activities and all requirements, including effective contraception (viz., a double-barrier method) during the 7-day study surveillance period.
Exclusion Criteria:
- Hematology, serum chemistry (exclusive of electrolytes), and urinalysis laboratory test values >2 times upper limits of normal or anemia (hemoglobulin <11 g/dL), leukopenia (total white blood count <3,000/µL or total neutrophils <1,500/ µL) or thrombocytopenia (platelets <100,000/µL). Electrolytes and coagulation values exceeding normal ranges are to be excluded.
- Body Mass Index (BMI) >35.
- Calculated creatinine clearance (by the Cockroft and Gault Formula) <70 mL/min, based on age and gender.
- Positive HIV-1 or HIV-2 serology.
- Positive HCV serology and/or positive plasma HCV-RNA status.
- Positive Hepatitis B status.
- Solid or hematopoetic organ transplant recipient.
- Active illness or recent illness within 30 days of the first dose of study drug.
- History of any of the following: brain injury, neoplasm, chronic or migraine headaches, cancer, meningitis or hydrocephalus.
- Usage of any prescribed, over-the-counter or illicit drug(s) within 30 days of study drug administration. Use of herbal remedies and/or supplements at the discretion of the Investigator.
- Unwilling to practice effective contraception during the study period.
- Participation in any clinical interventional trial within the previous 6 months.
- Positive drug urine screen.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To determine if the study drug penetrates the blood brain barrier following a single dose of AVI-4020, and if it does, the associated CSF, plasma and urine pharmacokinetics
|
Secondary Outcome Measures
Outcome Measure |
---|
Safety, Tolerability
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paula M Shaw, M.D., NW Kinetics
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- AVI-4020-21b
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on West Nile Virus
-
Institute of Tropical Medicine, BelgiumUniversiteit Antwerpen; Victor Babes Hospital, Bucharest, RomaniaWithdrawnOxidative Stress | West Nile Virus | West Nile Fever | West Nile Fever Encephalitis | West Nile Fever Meningitis | West Nile Meningitis | West Nile Virus Meningoencephalitis | West Nile Fever Meningoencephalitis | West Nile Fever With Neurologic ManifestationRomania
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedWest Nile VirusUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Leiden University Medical CenterUMC Utrecht; Erasmus Medical Center; Leiden University; Netherlands Institute of...Completed
-
Hawaii Biotech, Inc.Completed
-
National Institutes of Health Clinical Center (CC)CompletedEncephalitis | Myelitis | West Nile VirusUnited States
-
National Institutes of Health Clinical Center (CC)CompletedWest Nile VirusUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)TerminatedEncephalitis | Meningitis | West Nile Virus Infection | West Nile Fever | West Nile Neuroinvasive Disease | Acute Flaccid Paralysis
-
National Institute of Allergy and Infectious Diseases...Completed
Clinical Trials on AVI-4020 Injection
-
Sarepta Therapeutics, Inc.Terminated
-
Sarepta Therapeutics, Inc.CompletedEncephalitisUnited States
-
Sarepta Therapeutics, Inc.Terminated
-
Sarepta Therapeutics, Inc.CompletedNeoplasmsUnited States
-
Sarepta Therapeutics, Inc.British Medical Research CouncilCompletedDuchenne Muscular DystrophyUnited Kingdom
-
Imperial College LondonSarepta Therapeutics, Inc.; Department of Health, United KingdomCompletedDuchenne Muscular DystrophyUnited Kingdom
-
Sarepta Therapeutics, Inc.United States Department of DefenseCompletedMarburg Hemorrhagic FeverUnited States
-
Sarepta Therapeutics, Inc.TerminatedCardiovascular Disease | Coronary Artery BypassUkraine
-
Chinese University of Hong KongNot yet recruitingArterial Stiffness
-
Sarepta Therapeutics, Inc.United States Department of DefenseCompletedEbola Hemorrhagic FeverUnited States